CANC — Tema Oncology ETF
Data updated: 2026-07-29
CANC — Tema Oncology ETF. United States Multi-Cap / All-Cap Blend / Core Health Care Equity · $176.14M AUM. Holdings, fees, performance and SEC filings.
CANC Fund Overview
CANC — Tema Oncology ETF is a US ETF managed by Tema ETF Trust, categorised as United States Multi-Cap / All-Cap Blend / Core Health Care Equity. ABC INVEST provides holdings, performance, costs, cashflows, risk data, prospectus documents and SEC filings, sourced from SEC filings.
- Type: US ETF
- Manager: Tema ETF Trust
- Category: United States Multi-Cap / All-Cap Blend / Core Health Care Equity
- Assets under management: $176.14M
- 1-year return: 60.0%
- Ticker: CANC
- SEC CIK: 0001944285
- SEC series ID: S000078299
- Share class ID: C000239059
CANC Holdings
Top 10 holdings of Tema Oncology ETF by percentage of net assets, from the fund's latest SEC N-PORT filing.
| Holding | % of net assets |
|---|---|
| Revolution Medicines Inc | 7.73% |
| Eli Lilly & Co | 4.82% |
| Roche Holding AG | 4.21% |
| Cogent Biosciences Inc | 4.10% |
| Novartis AG | 4.03% |
| Immunome Inc | 3.91% |
| Celcuity Inc | 3.58% |
| Merck & Co Inc | 3.57% |
| AstraZeneca PLC | 3.54% |
| Nuvalent Inc | 3.37% |
CANC Portfolio Allocation
Asset-class allocation of Tema Oncology ETF by percentage of net assets, from the latest SEC N-PORT filing.
| Asset class | Allocation |
|---|---|
| Equity | 99.0% |
| Cash & Equivalents | 1.1% |
CANC Performance
Total returns for CANC (as of 2026-09-01), from SEC filings.
| Period | Total return |
|---|---|
| YTD | 9.8% |
| 1 year | 60.0% |
| 3 years (annualised) | 17.2% |
CANC Risk Information
Risk metrics for CANC, derived from monthly returns in SEC filings.
- 1-year volatility (annualised): 17.2%
CANC Costs and Fees
CANC costs about $75 per $10,000 invested per year in fund expenses.
- Net expense ratio: 0.75%
- Gross expense ratio: 0.99%
- Portfolio turnover: 68%
- Brokerage commissions: 4.22 bps of average net assets (SEC N-CEN)
CANC Cashflows
Over the 12 months to 2026-05, Tema Oncology ETF had net inflows of $65.22M, from monthly SEC N-PORT filings.
| Month | Net flow |
|---|---|
| 2026-05 | −$2.27M |
| 2026-04 | $3.51M |
| 2026-03 | $13.14M |
| 2026-02 | $9.03M |
| 2026-01 | $23.51M |
| 2025-12 | $13.57M |
CANC Debt Constituents
No individual debt constituents are reported in Tema Oncology ETF's latest SEC N-PORT filing.
CANC Prospectus and SEC Filings
Official Tema Oncology ETF filings on SEC EDGAR — prospectus, portfolio holdings and annual reports.
- Prospectus (485BPOS) — filed 2026-06-29
- Prospectus (485BPOS) — filed 2025-06-26
- Prospectus supplement (497) — filed 2026-02-09
- Portfolio holdings (N-PORT) — filed 2026-07-29
- Portfolio holdings (N-PORT) — filed 2026-04-23
- Portfolio holdings (N-PORT) — filed 2026-01-21
- Annual census (N-CEN) — filed 2026-05-14
- Annual census (N-CEN) — filed 2025-05-13
Related Funds
Other United States Multi-Cap / All-Cap Blend / Core Health Care Equity funds tracked on ABC INVEST:
Data Sources
ABC INVEST compiles this page from public filings made to the U.S. Securities and Exchange Commission (SEC) through EDGAR: portfolio holdings and monthly cashflows from Form N-PORT, expenses and returns from fund prospectuses (Form 485BPOS) and the SEC DERA Risk/Return Summary data sets, annual data from Form N-CEN, and shareholder reports from Form N-CSR.